RG
AZN icon

Redmile Group’s AstraZeneca AZN Stock Holding History

Redmile Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,010,800
Closed -$70.2M – 66
2017
Q4 		$70.2M Sell
1,010,800
-112,350
-10% -$7.58M 3.05% 7
2017
Q3 		$76.1M Buy
+1,123,150
New +$71M 3.75% 7
2016
Q4 		– Sell
-144,178
Closed -$9.47M – 51
2016
Q3 		$9.47M Buy
+144,178
New +$9.42M 0.75% 32
2015
Q1 		– Sell
-258,305
Closed -$18.2M – 55
2014
Q4 		$18.2M Buy
+258,305
New +$18.5M 1.98% 16
2014
Q1 		– Sell
-511,120
Closed -$30.3M – 57
2013
Q4 		$30.3M Buy
511,120
+275,020
+116% +$14.9M 3.74% 5
2013
Q3 		$12.3M Buy
+236,100
New +$11.9M 1.85% 25

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Redmile Group's AZN Position: Q1 2018 in Review

Redmile Group sold out of AstraZeneca (AZN) in Q1 2018, closing a stake of 1,010,800 shares — an estimated $70.2M sold.

Redmile Group first reported a position in AZN in Q3 2013 and held it in 6 quarters. The position peaked at $76.1M in Q3 2017. 519 funds tracked by Wall St. Rank hold AZN as of Q1 2018.

  • Redmile Group reported no remaining AstraZeneca position as of Q1 2018 after selling out during the quarter.
  • Redmile Group sold 1,010,800 AstraZeneca shares in Q1 2018, an estimated $70.2M.
  • Redmile Group first reported a position in AstraZeneca in Q3 2013 and held it in 6 quarters.
  • Redmile Group's AstraZeneca position peaked at $76.1M in Q3 2017.
  • 519 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2018.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.